StageZero Life Sciences Announces Results on Resolutions at Annual and Special Meeting
TORONTO, ON / ACCESSWIRE / June 28, 2022 / StageZero Life Sciences, Ltd (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company") is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company's management …
TORONTO, ON / ACCESSWIRE / June 28, 2022 / StageZero Life Sciences, Ltd (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company") is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company's management information circular dated May 12, 2022 (the "Circular"), at its annual and special meeting of shareholders held on June 28, 2022 (the "Meeting").
The results of the vote for the election of directors are as follows:
For |
Withheld |
|
James Howard-Tripp |
84% |
16% |
Rory Riggs |
89% |
11% |
Harry Glorikian |
89% |
11% |
Garth MacRae |
89% |
11% |
Shareholders also voted in favour of the following matters:
- Appointment of SRCO Professional Services LLP as auditors of the Company with 97% votes for; and
- Stock Option Plan renewal - 77% votes for.
"2021 was a very significant year for us and 2022 is shaping up to be equally as important as we bring the full force of the consolidated company into focus. With our integrated programs now launched, it is for us to build on the momentum we are creating with existing, and new partners, generate significant revenue, and manage costs, so we get to full autonomy. We look forward to it and thank you, our shareholders, for your continuing support" said James Howard-Tripp, Chairman and CEO, StageZero Life Sciences.
More specific details of the matters approved at the Meeting are set forth in the Circular and posted on the System for Electronic Data Analysis and Retrieval (SEDAR) at www.sedar.com. Voting results are released in accordance with Toronto Stock Exchange ("TSX") requirements.
Lesen Sie auch
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation
diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing
late-stage disease (AVRT™).